Law360, New York ( April 2, 2012, 12:27 PM EDT) -- Over the last eight months, a number of courts have been called upon to interpret and apply the United States Supreme Court's June 2011 holding in PLIVA Inc. v. Mensing[1] that federal preemption bars failure-to-warn claims against a generic drug manufacturer whose labeling mirrors the U.S. Food and Drug Administration (FDA)-approved labeling for the brand-name counterpart of the generic product....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.